CVS suspends sales of Zantac brand and generic ranitidine products over cancer fears
CVS Pharmacy announced Saturday that it has suspended the sale of all Zantac brand and CVS Health brand ranitidine products until further notice.
This action is being taken out of an abundance of caution due to a recent product alert from the U.S. Food and Drug Administration (FDA) that ranitidine products may contain a low level of nitrosodimethylamine (NDMA), which is a probable human carcinogen.
The FDA is continuing to evaluate whether low levels of NDMA in ranitidine pose a risk to patients. The levels that FDA is finding in ranitidine from preliminary tests barely exceed amounts found in common foods.
Zantac brand products and CVS brand ranitidine products have not been recalled, and the FDA is not recommending that patients stop taking ranitidine at this time. However, customers who purchased these products can return them to CVS for a refund.
Ranitidine is an H2 Blocker that is taken to provide heartburn relief. CVS Pharmacy will continue to sell other over-the-counter H2 Blockers, including Pepcid, Tagamet and its respective generic equivalents, famotidine and cimetidine.
Consumers seeking alternate therapy to treat their condition should speak with their healthcare provider or a CVS pharmacist. CVS pharmacists are always available to discuss any questions or concerns that customers may have about their medications.
